Tandem Diabetes Care Announces Third Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance
Tandem Diabetes Care (TNDM) reported strong Q3 2024 financial results with worldwide GAAP sales increasing 31% to $244.0 million. The company achieved its highest quarterly sales in history, both domestically and internationally. Worldwide pump shipments grew by over 25% compared to Q3 2023, with approximately 21,000 pumps shipped in the US and nearly 11,000 internationally. The company demonstrated positive Adjusted EBITDA of $4.0 million (2% of sales) and returned to positive free cash flow. Despite these improvements, TNDM still reported a GAAP net loss of $23.3 million, though this was an improvement from the $33.0 million loss in Q3 2023.
Tandem Diabetes Care (TNDM) ha riportato risultati finanziari solidi per il terzo trimestre del 2024, con vendite globali GAAP aumentate del 31% a $244,0 milioni. L'azienda ha raggiunto il suo massimo storico di vendite trimestrali, sia a livello nazionale che internazionale. Le spedizioni di pompe in tutto il mondo sono cresciute di oltre il 25% rispetto al terzo trimestre del 2023, con circa 21.000 pompe spedite negli Stati Uniti e quasi 11.000 a livello internazionale. L'azienda ha registrato un EBITDA rettificato positivo di $4,0 milioni (2% delle vendite) ed è tornata a generare flusso di cassa libero positivo. Nonostante questi miglioramenti, TNDM ha riportato comunque una perdita netta GAAP di $23,3 milioni, ma questa rappresenta un miglioramento rispetto alla perdita di $33,0 milioni del terzo trimestre del 2023.
Tandem Diabetes Care (TNDM) reportó resultados financieros sólidos para el tercer trimestre de 2024, con ventas globales GAAP que aumentaron un 31% a $244,0 millones. La compañía alcanzó sus ventas trimestrales más altas en la historia, tanto a nivel nacional como internacional. Los envíos de bombas a nivel mundial crecieron más del 25% en comparación con el tercer trimestre de 2023, con aproximadamente 21,000 bombas enviadas en Estados Unidos y casi 11,000 internacionalmente. La compañía demostró un EBITDA ajustado positivo de $4,0 millones (2% de las ventas) y volvió a tener un flujo de caja libre positivo. A pesar de estas mejoras, TNDM aún reportó una pérdida neta GAAP de $23,3 millones, aunque esto fue una mejora respecto a la pérdida de $33,0 millones en el tercer trimestre de 2023.
탄덤 다이어베티스케어(TNDM)는 2024년 3분기 강력한 재무 실적을 보고하며, 전 세계 GAAP 매출이 31% 증가하여 $244.0 백만에 달했습니다. 이 회사는 국내외에서 분기별 매출 사상 최고치를 달성했습니다. 전 세계 펌프 출하량은 2023년 3분기 대비 25% 이상 증가하여 미국에서 약 21,000대, 해외에서 거의 11,000대의 펌프가 출하되었습니다. 이 회사는 조정된 EBITDA가 $4.0 백만(매출의 2%)으로 긍정적인 모습을 보였고, 긍정적인 자유현금을 회복했습니다. 이러한 개선에도 불구하고 TNDM은 여전히 GAAP 기준으로 $23.3 백만의 순손실을 보고했으나, 이는 2023년 3분기의 $33.0 백만 손실보다 개선된 수치입니다.
Tandem Diabetes Care (TNDM) a annoncé de solides résultats financiers pour le troisième trimestre 2024, avec des ventes mondiales GAAP en augmentation de 31% à 244,0 millions USD. L'entreprise a atteint ses ventes trimestrielles les plus élevées de l'histoire, tant sur le marché national qu'international. Les expéditions de pompes à l'échelle mondiale ont augmenté de plus de 25% par rapport au troisième trimestre 2023, avec environ 21 000 pompes expédiées aux États-Unis et près de 11 000 à l'international. L'entreprise a démontré un EBITDA ajusté positif de 4,0 millions USD (2% des ventes) et est revenue à un flux de trésorerie libre positif. Malgré ces améliorations, TNDM a tout de même rapporté une perte nette GAAP de 23,3 millions USD, bien que cela représente une amélioration par rapport à la perte de 33,0 millions USD du troisième trimestre 2023.
Tandem Diabetes Care (TNDM) hat für das dritte Quartal 2024 starke Finanzergebnisse gemeldet, mit einem Anstieg der weltweiten GAAP-Verkäufe um 31% auf 244,0 Millionen USD. Das Unternehmen erzielte den höchsten Quartalsumsatz seiner Geschichte, sowohl im Inland als auch international. Die weltweiten Pumpenlieferungen stiegen im Vergleich zum dritten Quartal 2023 um mehr als 25%, wobei etwa 21.000 Pumpen in den USA und fast 11.000 international geliefert wurden. Das Unternehmen wies ein positives bereinigtes EBITDA von 4,0 Millionen USD (2% des Umsatzes) aus und kehrte zu einem positiven freien Cashflow zurück. Trotz dieser Verbesserungen meldete TNDM jedoch weiterhin einen GAAP-Nettoverlust von 23,3 Millionen USD, was jedoch eine Verbesserung gegenüber dem Verlust von 33,0 Millionen USD im dritten Quartal 2023 darstellt.
- Record quarterly sales with 31% YoY growth to $244.0 million
- Worldwide pump shipments increased over 25% YoY
- Positive Adjusted EBITDA of $4.0 million (2% of sales)
- Return to positive free cash flow
- Gross margin improved to 51% from 48% YoY
- GAAP operating loss of $26.1 million (11% of sales)
- Net loss of $23.3 million despite revenue growth
- Non-GAAP operating loss of $26.5 million (11% of sales)
Insights
The Q3 results demonstrate significant operational improvements for Tandem Diabetes Care. Sales grew 31% year-over-year to
Key positive indicators include:
- Return to positive free cash flow
- Positive Adjusted EBITDA of
$4.0 million (2% of sales) - Improved gross margin to
51% - Growth in new pump starts in the US market
The completion of clinical studies for Control-IQ technology in type 2 diabetes represents a significant strategic advancement. The potential expansion into the type 2 diabetes market could substantially increase Tandem's addressable market, as type 2 represents approximately
Third Quarter 2024 Highlights
-
Worldwide GAAP sales increased 31 percent to
compared to third quarter 2023; worldwide non-GAAP sales(1) increased 25 percent to$244.0 million compared to third quarter 2023.$242.9 million - Grew worldwide pump shipments by more than 25 percent compared to third quarter 2023.
-
Achieved year-over-year growth in new pump starts in
the United States , including growth in new customers starting from multiple daily injections. - Demonstrated positive Adjusted EBITDA and a return to positive free cash flow.
- Completed clinical study in support of a regulatory filing to expand the indication for Control-IQ to include people living with type 2 diabetes.
“The third quarter marked a milestone achievement for Tandem Diabetes Care as we delivered the highest quarterly sales in our Company’s history, both in the
Third Quarter 2024 Sales Results Compared to 2023
From September 2022 through February 2024, the Company offered the Tandem Choice Program (Tandem Choice) to eligible t:slim X2 customers to provide a pathway to ownership of Tandem Mobi, for a fee when available. At the end of the second quarter, the Company began offering eligible t:slim X2 owners the opportunity to switch to a Tandem Mobi under the terms of Tandem Choice. As a result of this program, the Company is providing select financial results on both a GAAP and non-GAAP basis. Additional information, including the accounting treatment of this program and other non-GAAP measures, can be found under Table D “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release. See also “Non-GAAP Financial Measures” below.
|
Three Months Ended |
|
|
Nine Months Ended |
||||||||||||||||||||||||||||||
|
September 30, |
|
|
September 30, |
||||||||||||||||||||||||||||||
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
||||||||||||||||||||||||
($ in millions) |
GAAP |
|
Non- GAAP(1) |
|
|
GAAP |
|
Non- GAAP(1) |
|
|
GAAP |
|
Non- GAAP(1) |
|
|
GAAP |
|
Non- GAAP(1) |
||||||||||||||||
|
$ |
171.7 |
|
$ |
170.6 |
|
|
$ |
130.2 |
|
$ |
138.5 |
|
|
$ |
458.1 |
|
$ |
458.0 |
|
|
$ |
404.0 |
|
$ |
416.5 |
||||||||
Outside |
|
72.3 |
|
|
|
72.3 |
|
|
|
|
55.4 |
|
|
|
55.4 |
|
|
|
|
199.5 |
|
|
|
199.5 |
|
|
|
|
146.9 |
|
|
|
146.9 |
|
Total Worldwide |
$ |
244.0 |
|
|
$ |
242.9 |
|
|
|
$ |
185.6 |
|
|
$ |
193.9 |
|
|
|
$ |
657.6 |
|
|
$ |
657.5 |
|
|
|
$ |
550.9 |
|
|
$ |
563.4 |
|
Third Quarter 2024 Additional Results Compared to Third Quarter 2023
-
Sales: In
the United States , GAAP sales included incremental sales relating to Tandem Choice compared to a sales deferral of$1.0 million . Non-GAAP sales exclude Tandem Choice-related sales deferrals or recognition.$8.2 million
Shipments inthe United States were approximately 21,000 pumps, which does not include pumps fulfilled under Tandem Choice. Shipments outsidethe United States were nearly 11,000 pumps.
-
Gross profit: GAAP gross profit was
, compared to$124.7 million . GAAP gross margin was 51 percent compared to 48 percent.$89.8 million
Non-GAAP gross profit(1) was compared to$124.3 million . Non-GAAP gross margin(1) was 51 percent in both periods.$98.0 million
-
Operating loss: GAAP operating loss was
, or negative 11 percent of sales, compared to$26.1 million , or negative 17 percent of sales.$31.5 million
Non-GAAP operating loss(1) was , or negative 11 percent of sales, compared to$26.5 million , or negative 12 percent of sales.$23.3 million
-
Net loss: GAAP net loss was
, compared to$23.3 million .$33.0 million
Non-GAAP net loss(1) was compared to$23.6 million .$24.7 million
Adjusted EBITDA(1) was , or 2 percent of sales, compared to$4.0 million , or 1 percent of sales.$1.5 million
(1) A reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures and additional information can be found in Table D “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release. Also see “Non-GAAP Financial Measures” below for additional information.
See tables for additional financial information.
2024 Financial Guidance
The Company’s non-GAAP guidance for the fiscal year ending December 31, 2024 is set forth below. The most directly comparable GAAP financial measures are not accessible on a forward-looking basis due to the high degree of complexity in the accounting treatment for the Tandem Choice program. For a description of non-GAAP sales, non-GAAP gross margin, and Adjusted EBITDA margin, as well as an illustration of the reconciliation from the most directly comparable GAAP financial measures, refer to Table D “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release. Also see “Non-GAAP Financial Measures” below for additional information.
For the year ending December 31, 2024, the Company is increasing 2024 sales guidance and reaffirming other financial guidance as follows:
-
Non-GAAP sales are estimated to be approximately
to$903 million for the full year.$910 million -
Sales in
the United States of to$645 million .$650 million -
Sales outside
the United States of approximately to$258 million .$260 million
-
Sales in
- Non-GAAP gross margin is estimated to be approximately 51 percent.
- Adjusted EBITDA margin is estimated to be breakeven as a percent of sales.
-
Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately
. This includes:$120 million -
Approximately
non-cash, stock-based compensation expense.$100 million -
Approximately
depreciation and amortization expense.$20 million
-
Approximately
Non-GAAP Financial Measures
Certain non-GAAP financial measures are presented in this press release to provide information that may assist investors in understanding the Company’s financial results and assessing its prospects for future performance. The Company believes these non-GAAP financial measures are important operating performance indicators because they exclude items that are unrelated to, and may not be indicative of, the Company’s core operating results. These non-GAAP financial measures, as calculated, may not necessarily be comparable to similarly titled measures of other companies and may not be appropriate measures for comparing the performance of other companies relative to the Company. These non-GAAP financial results are not intended to represent, and should not be considered to be more meaningful measures than, or alternatives to, measures of operating performance as determined in accordance with GAAP. To the extent the Company uses such non-GAAP financial measures in the future, they will be calculated using a consistent method from period to period. A reconciliation of each of the historical GAAP financial measures to the most directly comparable historical non-GAAP financial measures has been provided in Table D “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release.
The Company has not provided a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures in reliance on the “unreasonable efforts” exception set forth in the applicable regulations, because there is substantial uncertainty associated with predicting any future adjustments that may be made to the Company’s GAAP financial measures in calculating the non-GAAP financial measures.
In particular, the accounting treatment for Tandem Choice has a high degree of complexity. In September 2022 when the program was launched, the Company began deferring a portion of sales for each eligible t:slim X2 pump shipped in
Notably:
- Offering the program does not impact the economics associated with how or when the initial pump sale is reimbursed.
- Customer eligibility for Tandem Choice was automatic at the time of a t:slim X2 purchase. Customer eligibility ended in February 2024 with the commercial availability of Tandem Mobi.
- Qualifying customers were able to elect participation in Tandem Choice starting at the end of the second quarter of 2024.
-
An affirmative election is required for the customer to participate in Tandem Choice, at which time any customer fees will be received and recognized as a sale. Any remaining deferrals are expected to be recognized in the fourth quarter of 2024. The balance of the Tandem Choice deferral was
as of September 30, 2024.$30.1 million - The expiration date of Tandem Choice is December 31, 2024.
Conference Call
The Company will hold a conference call and simultaneous webcast today at 4:30pm Eastern Time (1:30pm Pacific Time). The link to the webcast will be available by accessing the Events & Presentations tab in the Investor Center of the Tandem Diabetes Care website at http://investor.tandemdiabetes.com, and will be archived for 30 days. To access the call by phone, please use this link (https://register.vevent.com/register/BI21747dfdc3fd4a4e98aeeeef73bf87b6) and you will be provided with dial-in details, including a personal pin.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in
Tandem Diabetes Care, the Tandem logo, Control-IQ, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding, among other things, the Company’s projected financial results and the ability to achieve other operational and commercial goals. The Company’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, the Company’s ability to achieve projected financial results will be impacted by market acceptance of the Company’s products; products marketed and sold or under development by competitors; the Company’s ability to establish and sustain operations to support international sales, including expanding into additional geographies; changes in reimbursement rates or insurance coverage for the Company’s products; the Company’s ability to meet increasing operational and infrastructure requirements from higher customer interest and a larger base of existing customers; the Company’s ability to successfully commercialize its products; the Company’s ability to develop and launch new products; risks associated with the regulatory approval process outside
TANDEM DIABETES CARE, INC. |
|||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
|||||||
Table A |
|||||||
(in thousands) |
|||||||
|
|
|
|
||||
|
September 30, |
|
December 31, |
||||
|
|
2024 |
|
|
|
2023 |
|
Assets |
(Unaudited) |
|
|
||||
Current assets: |
|
|
|
||||
Cash, cash equivalents and short-term investments |
$ |
473,305 |
|
$ |
467,912 |
||
Accounts receivable, net |
|
107,188 |
|
|
|
105,555 |
|
Inventories |
|
152,441 |
|
|
|
157,937 |
|
Other current assets |
|
19,892 |
|
|
|
16,585 |
|
Total current assets |
|
752,826 |
|
|
|
747,989 |
|
|
|
|
|
||||
Property and equipment, net |
|
81,064 |
|
|
|
76,542 |
|
Operating lease right-of-use assets |
|
87,393 |
|
|
|
87,791 |
|
Other long-term assets |
|
36,447 |
|
|
|
40,336 |
|
Total assets |
$ |
957,730 |
|
|
$ |
952,658 |
|
|
|
|
|
||||
Liabilities and Stockholders’ Equity |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable, accrued expenses and employee-related liabilities |
$ |
119,752 |
|
|
$ |
105,742 |
|
Current portion of convertible senior notes, net |
|
40,605 |
|
|
|
— |
|
Operating lease liabilities |
|
18,033 |
|
|
|
17,060 |
|
Deferred revenue |
|
42,567 |
|
|
|
43,994 |
|
Other current liabilities |
|
38,319 |
|
|
|
28,462 |
|
Total current liabilities |
|
259,276 |
|
|
|
195,258 |
|
|
|
|
|
||||
Convertible senior notes, net - long-term |
|
307,829 |
|
|
|
285,035 |
|
Operating lease liabilities - long-term |
|
109,479 |
|
|
|
113,572 |
|
Deferred revenue - long-term |
|
11,196 |
|
|
|
13,331 |
|
Other long-term liabilities |
|
32,240 |
|
|
|
31,830 |
|
Total liabilities |
|
720,020 |
|
|
|
639,026 |
|
|
|
|
|
||||
Total stockholders’ equity |
|
237,710 |
|
|
|
313,632 |
|
Total liabilities and stockholders’ equity |
$ |
957,730 |
|
|
$ |
952,658 |
|
TANDEM DIABETES CARE, INC. |
|||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
|||||||||||||||
Table B |
|||||||||||||||
(in thousands, except per share data) |
|||||||||||||||
(Unaudited) |
|||||||||||||||
|
|
|
|
|
|
||||||||||
|
Three Months Ended September 30, |
|
Nine months ended September 30, |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Sales |
$ |
243,971 |
|
|
$ |
185,622 |
|
|
$ |
657,555 |
|
|
$ |
550,922 |
|
Cost of sales |
|
119,318 |
|
|
|
95,869 |
|
|
|
325,436 |
|
|
|
276,527 |
|
Gross profit |
|
124,653 |
|
|
|
89,753 |
|
|
|
332,119 |
|
|
|
274,395 |
|
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Selling, general and administrative |
|
99,639 |
|
|
|
79,328 |
|
|
|
283,987 |
|
|
|
266,752 |
|
Research and development |
|
51,107 |
|
|
|
41,970 |
|
|
|
146,677 |
|
|
|
127,063 |
|
Acquired in-process research and development expenses |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
78,750 |
|
Total operating expenses |
|
150,746 |
|
|
|
121,298 |
|
|
|
430,664 |
|
|
|
472,565 |
|
Operating loss |
|
(26,093 |
) |
|
|
(31,545 |
) |
|
|
(98,545 |
) |
|
|
(198,170 |
) |
Total other income (expense), net |
|
3,479 |
|
|
|
816 |
|
|
|
6,659 |
|
|
|
9,226 |
|
Loss before income taxes |
|
(22,614 |
) |
|
|
(30,729 |
) |
|
|
(91,886 |
) |
|
|
(188,944 |
) |
Income tax expense |
|
637 |
|
|
|
2,232 |
|
|
|
4,894 |
|
|
|
3,665 |
|
Net loss |
$ |
(23,251 |
) |
|
$ |
(32,961 |
) |
|
$ |
(96,780 |
) |
|
$ |
(192,609 |
) |
|
|
|
|
|
|
|
|
||||||||
Net loss per share - basic and diluted |
$ |
(0.35 |
) |
|
$ |
(0.51 |
) |
|
$ |
(1.48 |
) |
|
$ |
(2.97 |
) |
|
|
|
|
|
|
|
|
||||||||
Weighted average shares used to compute basic and diluted net loss per share |
|
65,538 |
|
|
|
65,117 |
|
|
|
65,287 |
|
|
|
64,834 |
|
TANDEM DIABETES CARE, INC. |
|||||||||||||||||||||
SALES BY GEOGRAPHY |
|||||||||||||||||||||
Table C(1) |
|||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
(Unaudited) |
|
|
|
|
|
|
|
|
||||||||||||
($'s in thousands) |
Three Months Ended September 30, |
|
|
|
Nine months ended September 30, |
|
|
||||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
% Change |
|
|
2024 |
|
|
|
2023 |
|
|
% Change |
||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Pump |
$ |
86,722 |
|
$ |
66,365 |
|
31 |
% |
|
$ |
230,187 |
|
$ |
207,180 |
|
11 |
% |
||||
Supplies and other |
|
83,889 |
|
|
|
72,093 |
|
|
16 |
% |
|
|
227,888 |
|
|
|
209,352 |
|
|
9 |
% |
Net revenue recognized (deferred) for Tandem Choice |
|
1,039 |
|
|
|
(8,236 |
) |
|
113 |
% |
|
|
47 |
|
|
|
(12,568 |
) |
|
100 |
% |
Total GAAP Sales in |
$ |
171,650 |
|
|
$ |
130,222 |
|
|
32 |
% |
|
$ |
458,122 |
|
|
$ |
403,964 |
|
|
13 |
% |
Adjustment for Tandem Choice |
|
(1,039 |
) |
|
|
8,236 |
|
|
(113 |
)% |
|
|
(47 |
) |
|
|
12,568 |
|
|
(100 |
)% |
Total Non-GAAP Sales in |
$ |
170,611 |
|
|
$ |
138,458 |
|
|
23 |
% |
|
$ |
458,075 |
|
|
$ |
416,532 |
|
|
10 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Outside |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Pump |
$ |
28,077 |
|
|
$ |
21,672 |
|
|
30 |
% |
|
$ |
79,774 |
|
|
$ |
67,235 |
|
|
19 |
% |
Supplies and other |
|
44,244 |
|
|
|
33,728 |
|
|
31 |
% |
|
|
119,659 |
|
|
|
79,723 |
|
|
50 |
% |
Total Sales Outside the United States |
$ |
72,321 |
|
|
$ |
55,400 |
|
|
31 |
% |
|
$ |
199,433 |
|
|
$ |
146,958 |
|
|
36 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Total GAAP Worldwide Sales |
$ |
243,971 |
|
|
$ |
185,622 |
|
|
31 |
% |
|
$ |
657,555 |
|
|
$ |
550,922 |
|
|
19 |
% |
Adjustment for Tandem Choice |
|
(1,039 |
) |
|
|
8,236 |
|
|
(113 |
)% |
|
|
(47 |
) |
|
|
12,568 |
|
|
(100 |
)% |
Total Non-GAAP Worldwide Sales |
$ |
242,932 |
|
|
$ |
193,858 |
|
|
25 |
% |
|
$ |
657,508 |
|
|
$ |
563,490 |
|
|
17 |
% |
(1) A reconciliation of non-GAAP financial measures to their closest GAAP equivalent and additional information can be found in Table D and under the heading “Reconciliation of GAAP versus Non-GAAP Financial Results.”
TANDEM DIABETES CARE, INC. |
|||||||||||||||
Reconciliation of GAAP versus Non-GAAP Financial Results (Unaudited) |
|||||||||||||||
Table D |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
($'s in thousands) |
Three Months Ended September 30, |
|
Nine months ended September 30, |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
GAAP sales |
$ |
243,971 |
|
|
$ |
185,622 |
|
|
$ |
657,555 |
|
|
$ |
550,922 |
|
Adjustment for Tandem Choice (1) |
|
(1,039 |
) |
|
|
8,236 |
|
|
|
(47 |
) |
|
|
12,568 |
|
Non-GAAP sales |
$ |
242,932 |
|
|
$ |
193,858 |
|
|
$ |
657,508 |
|
|
$ |
563,490 |
|
|
|
|
|
|
|
|
|
||||||||
GAAP gross profit |
$ |
124,653 |
|
|
$ |
89,753 |
|
|
$ |
332,119 |
|
|
$ |
274,395 |
|
Adjustment for Tandem Choice(1) |
|
(374 |
) |
|
|
8,236 |
|
|
|
645 |
|
|
|
12,568 |
|
Non-GAAP gross profit |
$ |
124,279 |
|
|
$ |
97,989 |
|
|
$ |
332,764 |
|
|
$ |
286,963 |
|
GAAP gross margin(2) |
|
51 |
% |
|
|
48 |
% |
|
|
51 |
% |
|
|
50 |
% |
Non-GAAP gross margin(3) |
|
51 |
% |
|
|
51 |
% |
|
|
51 |
% |
|
|
51 |
% |
|
|
|
|
|
|
|
|
||||||||
GAAP operating loss |
$ |
(26,093 |
) |
|
$ |
(31,545 |
) |
|
$ |
(98,545 |
) |
|
$ |
(198,170 |
) |
Acquired in-process research and development(4) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
78,750 |
|
Non-recurring facility consolidation costs(5) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
14,099 |
|
Severance costs - cash and noncash |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2,680 |
|
Adjustment for Tandem Choice(1) |
|
(374 |
) |
|
|
8,236 |
|
|
|
645 |
|
|
|
12,568 |
|
Non-GAAP operating loss |
$ |
(26,467 |
) |
|
$ |
(23,309 |
) |
|
$ |
(97,900 |
) |
|
$ |
(90,073 |
) |
GAAP operating margin(2) |
|
(11 |
)% |
|
|
(17 |
)% |
|
|
(15 |
)% |
|
|
(36 |
)% |
Non-GAAP operating margin(3) |
|
(11 |
)% |
|
|
(12 |
)% |
|
|
(15 |
)% |
|
|
(16 |
)% |
|
|
|
|
|
|
|
|
||||||||
GAAP net loss |
$ |
(23,251 |
) |
|
$ |
(32,961 |
) |
|
$ |
(96,780 |
) |
|
$ |
(192,609 |
) |
Income tax expense (benefit) |
|
637 |
|
|
|
2,232 |
|
|
|
4,894 |
|
|
|
3,665 |
|
Interest income, interest expense and other, net |
|
(3,479 |
) |
|
|
(816 |
) |
|
|
(6,659 |
) |
|
|
(9,226 |
) |
Depreciation and amortization |
|
4,211 |
|
|
|
4,023 |
|
|
|
12,362 |
|
|
|
11,684 |
|
Stock-based compensation expense |
|
26,281 |
|
|
|
20,741 |
|
|
|
73,217 |
|
|
|
64,946 |
|
Acquired in-process research and development(4) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
78,750 |
|
Non-recurring facility consolidation costs(5) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
14,099 |
|
Severance costs - cash and noncash |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2,680 |
|
Adjustment for Tandem Choice(1) |
|
(374 |
) |
|
|
8,236 |
|
|
|
645 |
|
|
|
12,568 |
|
Adjusted EBITDA |
$ |
4,025 |
|
|
$ |
1,455 |
|
|
$ |
(12,321 |
) |
|
$ |
(13,443 |
) |
Adjusted EBITDA margin(3) |
|
2 |
% |
|
|
1 |
% |
|
|
(2 |
)% |
|
|
(2 |
)% |
|
|
|
|
|
|
|
|
||||||||
GAAP net loss |
$ |
(23,251 |
) |
|
$ |
(32,961 |
) |
|
$ |
(96,780 |
) |
|
$ |
(192,609 |
) |
Acquired in-process research and development(4) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
78,750 |
|
Non-recurring facility consolidation costs(5) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
14,099 |
|
Severance costs - cash and noncash |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2,680 |
|
Adjustment for Tandem Choice(1) |
|
(374 |
) |
|
|
8,236 |
|
|
|
645 |
|
|
|
12,568 |
|
Non-GAAP net loss |
$ |
(23,625 |
) |
|
$ |
(24,725 |
) |
|
$ |
(96,135 |
) |
|
$ |
(84,512 |
) |
(1) The accounting treatment for Tandem Choice has a high degree of complexity. Additional information can be found under the heading “Non-GAAP Financial Measures.”
(2) GAAP margins including GAAP gross margin and GAAP operating margin are calculated using GAAP sales.
(3) Non-GAAP margins including non-GAAP gross margin, non-GAAP operating margin, and adjusted EBITDA margin are calculated using non-GAAP sales.
(4) Acquired in-process research and development charges representing the value of acquired in-process research and development assets with no alternative future use and acquisition related expenses recorded in connection with the acquisitions of AMF Medical SA in 2023.
(5) The Company recorded
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106987558/en/
Media Contact:
858-366-6900
media@tandemdiabetes.com
Investor Contact:
858-366-6900
IR@tandemdiabetes.com
Source: Tandem Diabetes Care, Inc.
FAQ
What was Tandem Diabetes Care's (TNDM) revenue growth in Q3 2024?
How many insulin pumps did TNDM ship in Q3 2024?
What was TNDM's gross margin in Q3 2024?